http://orcid.org/0000-0002-1068-4261
References
- Bateman KP, Trimble L, Chauret N, et al. (2006). Interspecies in vitro metabolism of the phosphodiesterase-4 (PDE4) inhibitor L-454,560. J Mass Spectrom 41:771–80.
- Chu ZL, Carroll C, Alfonso J, et al. (2008). A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology 149:2038–47.
- Chu ZL, Jones RM, He H, et al. (2007). A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148:2601–9.
- Gu C, Elmore CS, Lin J, et al. (2012). Metabolism of a G protein-coupled receptor modulator, including two major 1,2,4-oxadiazole ring-opened metabolites and a rearranged cysteine-piperazine adduct. Drug Metab Dispos 40:1151–63.
- Guengerich FP. (2005). Reduction of cytochrome b5 by NADPH-cytochrome P450 reductase. Arch Biochem Biophys 440:204–11.
- Inagaki N, Chou HS, Tsukiyama S, et al. (2017). Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a randomized, double-blind, placebo-controlled, parallel-group, multicenter, phase II study. BMJ 5:e000424.
- Lan SJ, Weliky I, Schreiber EC. (1973). Metabolic studies with trans-5-amino-3-(2-(5-nitro-2-furyl)vinyl)-1,2,4-(5- 14 C)oxadiazole (SQ 18,506). 1. Reductive cleavage of the 1,2,4-oxadiazole ring. Xenobiotica 3:97–102.
- Matsumoto K. (2016). DS-8500a, a novel orally available GPR119 agonist improves glucose tolerance in type 2 diabetic rats. New Orleans, LA: American Diabetes Association’s 76th Scientific Sessions, 1124-P.
- Nakasa H, Komiya M, Ohmori S, et al. (1993a). Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide. Drug Metab Dispos 21:777–81.
- Nakasa H, Komiya M, Ohmori S, et al. (1993b). Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol Pharmacol 44:216–21.
- Odori S, Hosoda K, Tomita T, et al. (2013). GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function. Metab Clin Exp 62:70–8.
- Speed W, Parton AH, Martin IJ, et al. (1994). The use of liquid chromatography/thermospray mass spectrometry with on-line ultraviolet diode array and radiochemical detection: characterization of the putative metabolites of U-78875 in female rat faeces. Biol Mass Spectr 23:1–5.
- Sugihara K, Kitamura S, Tatsumi K. (1996). Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. Drug Metab Dispos 4:199–202.
- Tsalta CD, Madatian A, Schubert EM, et al. (2011). Metabolism of [(14)C]GSK977779 in rats and its implication with the observed covalent binding. Drug Metab Dispos 39:1620–32.
- Walton MI, Wolf CR, Workman P. (1992). The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol 44:251–9.
- Zhang D, Raghavan N, Chen SY, et al. (2008). Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic clearance pathway in rats and dogs. Drug Metab Dispos 36:303–15.